

MEASLES SITUATION REPORT

Serial Number 11

Data as at November 30th 2020



HIGHLIGHTS

■ In November, 2020:

- A total of 53 suspected cases were reported of which 40(75.5%) were from Delta (8), Ekiti (7), Katsina (5) and four each from Oyo, Ogun, Sokoto, Imo and Lagos states
- Two (3.8%) were confirmed (1 lab confirmed & 1 clinically compatible), 8 (15.1%) were discarded and 43 (81.1%) are pending classification
- No new LGA reported a confirmed case and no death was recorded among confirmed cases

■ From January – November, 2020:

- Katsina (1,769), Sokoto (1,232), Yobe (1,202), Zamfara (1,102), Adamawa (750) and Kebbi (745) accounted for 47.0% of the 14,453 suspected cases reported
- A total of 9,238 (63.9%) were confirmed (2,438 lab confirmed 1,501 epi-linked and 5,299 clinically compatible), 4,528 (31.3%) were discarded and 687 (4.8%) were pending classification
- The age group 9 - 59 months accounted for 58.8% (5,431) of all confirmed cases
- A total of 55 deaths (CFR = 0.6%) were recorded among confirmed cases
- Up to 5,397 (58.4%) of the confirmed cases did not received any dose of measles vaccination (zero dose)

■ Measles outbreaks from January – November, 2020:

- Gummi LGA in Zamfara State recorded a new outbreak in this reporting month
- Of the 222 LGAs with reported outbreak this year, 10 LGAs across 8 states had an ongoing outbreak in November

SITUATION UPDATES

Total (New in this month)

SUSPECTED CASES

14,453 (53)

States With Suspected Cases

36 + FCT

LGAs with Suspected Cases

725 (2)

CONFIRMED CASES

9,238 (2)

States with Confirmed Cases

36 + FCT

LGAs with Confirmed Cases

599 (0)

DEATHS AMONG CONFIRMED CASES

55 (0)

MEASLES OUTBREAKS

222 (1)

States with Measles Outbreaks

32 + FCT (0)

LGAs with Measles Outbreaks

222 (1)



World Health Organization



DeHealth AFRICA

AFENET

NiMet



UNIVERSITY of MARYLAND



Table 1: Distribution of key measles surveillance variables by states, Jan – Nov, 2020

States	# Suspected cases	# Confirmed cases (%)	Classification of confirmed cases			% of confirmed cases aged 9-59 months	% of confirmed cases that are "zero dose"
			Lab. confirmed	Epi. linked	Clin. Compatible		
NORTH	10,475	8,466 (80.8%)	1,704	1,501	5,261	60.2%	61.4%
Adamawa	750	515 (68.7%)	237	227	51	35.9%	49.9%
Bauchi	603	574 (95.2%)	12	0	562	58.9%	0.2%
Benue	97	27 (27.8%)	24	0	3	48.1%	96.3%
Borno	678	556 (82.0%)	92	49	415	56.7%	69.2%
FCT	40	20 (50.0%)	15	0	5	30.0%	95.0%
Gombe	260	184 (70.8%)	36	115	33	51.6%	82.1%
Jigawa	608	358 (58.9%)	181	0	177	53.1%	75.7%
Kaduna	228	180 (78.9%)	63	0	117	53.3%	76.1%
Kano	261	221 (84.7%)	44	0	177	81.4%	96.8%
Katsina	1,769	1,591 (89.9%)	241	694	656	66.2%	28.6%
Kebbi	745	429 (57.6%)	195	0	234	46.2%	91.8%
Kogi	138	62 (44.9%)	56	0	6	41.9%	74.2%
Kwara	108	46 (42.6%)	40	0	6	32.6%	71.7%
Nasarawa	129	56 (43.4%)	27	22	7	51.8%	60.7%
Niger	269	185 (68.8%)	124	29	32	59.5%	97.8%
Plateau	133	69 (51.9%)	22	16	31	20.3%	85.5%
Sokoto	1,232	1,179 (95.7%)	55	0	1124	65.1%	94.3%
Taraba	123	54 (43.9%)	54	0	0	24.1%	3.7%
Yobe	1,202	1,099 (91.4%)	153	349	597	58.9%	58.3%
Zamfara	1,102	1,061 (96.3%)	33	0	1,028	76.1%	73.6%
SOUTH	3,978	772 (19.4%)	734	0	38	43.1%	25.6%
Abia	199	46 (23.1%)	44	0	2	28.3%	21.7%
Akwa Ibom	169	56 (33.1%)	53	0	3	44.6%	60.7%
Anambra	216	23 (10.6%)	21	0	2	34.8%	47.8%
Bayelsa	175	40 (22.9%)	38	0	2	60.0%	67.5%
Cross River	150	30 (20.0%)	28	0	2	30.0%	33.3%
Delta	276	75 (27.2%)	74	0	1	61.3%	68.0%
Ebonyi	83	19 (22.9%)	19	0	0	47.4%	73.7%
Edo	94	16 (17.0%)	14	0	2	50.0%	18.8%
Ekiti	459	43 (9.4%)	38	0	5	16.3%	0.0%
Enugu	266	27 (10.2%)	26	0	1	48.1%	7.4%
Imo	193	28 (14.5%)	28	0	0	35.7%	53.6%
Lagos	280	22 (7.9%)	22	0	0	54.5%	0.0%
Ogun	258	85 (32.9%)	79	0	6	50.6%	0.0%
Ondo	143	23 (16.1%)	22	0	1	30.4%	0.0%
Osun	448	96 (21.4%)	93	0	3	42.7%	0.0%
Oyo	374	100 (26.7%)	95	0	5	40.0%	0.0%
Rivers	195	43 (22.1%)	40	0	3	41.9%	48.8%
NATIONAL	14,453	9,238 (63.9%)	2,438	1,501	5,299	58.8%	58.4%




Figure 1: Distribution of LGAs with measles outbreak in Nigeria, Jan – Nov, 2020

Table 2: Summary of key measles surveillance variables, Jan – Nov, 2018 – 2020

Description of Cases (<i>source: case-based data</i>)	2018 (Jan – Nov)	2019 (Jan – Nov)	2020 (Jan – Nov)
# of suspected cases	13,023	37,221	14,453
• Number of LGAs with at least 1 suspected case	719	749	725
• Number of states with at least 1 suspected case	36 + FCT	36 + FCT	36 + FCT
# of suspected cases with blood collected	9,779	12,540	7,728
• Number of lab confirmed (IgM+)	1,265 (12.9%)	2,985 (23.8%)	2,438 (31.6%)
• Number of IgM- (Negative)	6,106 (62.4%)	9,169 (73.1%)	4,528 (58.6%)
• Number of IgM indeterminate	206 (2.1%)	277 (2.2%)	98 (1.3%)
• Number of samples not tested (not done)	81 (0.8%)	109 (0.9%)	7 (0.1%)
• Number of pending samples	2,121 (21.7%)	0	657 (8.5%)
# of confirmed cases	4,917	28,177	9,238
• Number of laboratory confirmed (IgM+)	1,265 (25.7%)	2,985 (10.6%)	2,438 (26.4%)
• Number of epidemiologically linked	1,047 (21.3%)	13,871 (49.2%)	1,501 (16.3%)
• Number of clinically compatible	2,605 (53.0%)	11,321 (40.2%)	5,299 (57.4%)
# of LGAs with at least 1 confirmed case	486	647	599
# of states with at least 1 confirmed case	36 + FCT	36 + FCT	36 + FCT
# of deaths among confirmed cases (CFR)	13 (0.3%)	152 (0.5%)	55 (0.6%)
# of measles outbreak (<i>source: lab data</i>)			
• # of LGAs with measles outbreak	105	203	222
• # of states with at least 1 LGA with measles outbreak	22 + FCT	33 + FCT	32 + FCT

Table 3: Trend of measles surveillance performance indicators, Jan – Nov, 2018 – 2020

Surveillance Performance Indicator	Target	2018 (Jan – Nov)	2019 (Jan – Nov)	2020 (Jan – Nov)
Measles Incidence	< 1/million population	24.0	133.5	42.4
Non-measles febrile rash illness (NMFRI) rate	≥ 2/100,000 population	3.0	4.3	2.1
Proportion of reported measles cases from whom blood specimen was collected	≥ 80%	75%	34%	53%
Proportion of LGAs that reported at least 1 measles case with blood specimen collected	≥ 80%	91%	94%	90%
Annualized rate of investigation (with blood specimens) of suspected measles cases	> 1/100,000 population	5.2	6.5	3.9
Proportion of lab confirmed measles cases	< 10%	17%	24%	35%
Proportion of serum specimens arriving measles laboratory in good condition	≥ 90%	88%	98%	84%




Figure 2: Trend of confirmed measles cases in Nigeria, 2018 – 2020 (epi-week 01 – 46)




Figure 3: Population rate of confirmed measles cases in Nigeria (North and South), Jan – Nov, 2020




Figure 4: Epi-curve of confirmed measles cases in Nigeria, 2018 – 2020 (Jan – Nov)




Figure 5: Epi-curve of confirmed measles cases in Nigeria (North and South), Jan – Nov, 2020




Figure 6: Vaccination status and age distribution of confirmed measles cases in Nigeria (North and South), Jan – Nov, 2020




Figure 7: Age-sex distribution of confirmed measles cases in Nigeria (North and South), Jan – Nov, 2020




Figure 8: Proportion of measles samples reaching the laboratory in good time by states, November 2020




Figure 9: Proportion of measles samples with good turn around time by reference laboratories, November 2020